Swiss National Bank’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.96M | Sell |
270,500
-3,300
| -1% | -$67.8K | ﹤0.01% | 1253 |
|
|
2026
Q1 | $5.26M | Hold |
273,800
| – | – | ﹤0.01% | 1339 |
|
|
2025
Q4 | $4.52M | Buy |
273,800
+6,300
| +2% | +$106K | ﹤0.01% | 1408 |
|
|
2025
Q3 | $3.88M | Buy |
267,500
+16,600
| +7% | +$239K | ﹤0.01% | 1464 |
|
|
2025
Q2 | $3.51M | Hold |
250,900
| – | – | ﹤0.01% | 1474 |
|
|
2025
Q1 | $3.41M | Sell |
250,900
-2,600
| -1% | -$49.8K | ﹤0.01% | 1475 |
|
|
2024
Q4 | $5.17M | Buy |
253,500
+2,800
| +1% | +$71.7K | ﹤0.01% | 1317 |
|
|
2024
Q3 | $7.3M | Buy |
250,700
+17,900
| +8% | +$444K | ﹤0.01% | 1094 |
|
|
2024
Q2 | $5.41M | Buy |
232,800
+14,600
| +7% | +$280K | ﹤0.01% | 1224 |
|
|
2024
Q1 | $4.48M | Buy |
218,200
+1,500
| +0.7% | +$28.2K | ﹤0.01% | 1362 |
|
|
2023
Q4 | $4.65M | Sell |
216,700
-24,100
| -10% | -$477K | ﹤0.01% | 1338 |
|
|
2023
Q3 | $4.97M | Buy |
240,800
+2,700
| +1% | +$68.5K | ﹤0.01% | 1283 |
|
|
2023
Q2 | $7.03M | Buy |
238,100
+32,900
| +16% | +$925K | ﹤0.01% | 1105 |
|
|
2023
Q1 | $4.73M | Sell |
205,200
-3,300
| -2% | -$90.8K | ﹤0.01% | 1314 |
|
|
2022
Q4 | $5.8M | Buy |
208,500
+4,400
| +2% | +$131K | ﹤0.01% | 1223 |
|
|
2022
Q3 | $6.26M | Buy |
204,100
+2,700
| +1% | +$87.8K | ﹤0.01% | 1147 |
|
|
2022
Q2 | $5.93M | Buy |
201,400
+13,700
| +7% | +$359K | ﹤0.01% | 1218 |
|
|
2022
Q1 | $6.04M | Buy |
187,700
+14,000
| +8% | +$482K | ﹤0.01% | 1329 |
|
|
2021
Q4 | $7.75M | Sell |
173,700
-400
| -0.2% | -$18.9K | ﹤0.01% | 1169 |
|
|
2021
Q3 | $8.78M | Buy |
174,100
+2,300
| +1% | +$130K | 0.01% | 1067 |
|
|
2021
Q2 | $13.5M | Sell |
171,800
-6,300
| -4% | -$390K | 0.01% | 862 |
|
|
2021
Q1 | $10.2M | Buy |
178,100
+3,300
| +2% | +$221K | 0.01% | 994 |
|
|
2020
Q4 | $14.6M | Sell |
174,800
-4,800
| -3% | -$290K | 0.01% | 754 |
|
|
2020
Q3 | $6.43M | Buy |
179,600
+3,100
| +2% | +$93.4K | 0.01% | 1021 |
|
|
2020
Q2 | $4.27M | Buy |
176,500
+55,400
| +46% | +$1.3M | ﹤0.01% | 1236 |
|
|
2020
Q1 | $2.12M | Buy |
121,100
+1,800
| +2% | +$37.5K | ﹤0.01% | 1422 |
|
|
2019
Q4 | $2.08M | Buy |
119,300
+3,000
| +3% | +$49.9K | ﹤0.01% | 1713 |
|
|
2019
Q3 | $1.78M | Buy |
116,300
+1,500
| +1% | +$28.7K | ﹤0.01% | 1740 |
|
|
2019
Q2 | $2.38M | Buy |
114,800
+2,300
| +2% | +$51.5K | ﹤0.01% | 1584 |
|
|
2019
Q1 | $2.61M | Buy |
112,500
+3,500
| +3% | +$73.2K | ﹤0.01% | 1488 |
|
|
2018
Q4 | $2.25M | Buy |
109,000
+1,900
| +2% | +$34.5K | ﹤0.01% | 1488 |
|
|
2018
Q3 | $2.33M | Buy |
107,100
+74,200
| +226% | +$1.23M | ﹤0.01% | 1622 |
|
|
2018
Q2 | $502K | Buy |
+32,900
| New | +$620K | ﹤0.01% | 2444 |
|
Other funds holding DNLI
N
Swiss National Bank's DNLI Position: Q2 2026 in Review
Swiss National Bank reduced its Denali Therapeutics (DNLI) stake by 1.2% in Q2 2026, selling an estimated $67.8K and leaving 270,500 shares worth $6.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1253.
Swiss National Bank first reported a position in DNLI in Q2 2018 and has held it in 33 quarters since. The position peaked at $14.6M in Q4 2020. 124 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Swiss National Bank held 270,500 shares of Denali Therapeutics worth $6.96M as of Q2 2026.
- Swiss National Bank sold 3,300 Denali Therapeutics shares in Q2 2026, an estimated $67.8K.
- Denali Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1253 holding.
- Swiss National Bank first reported a position in Denali Therapeutics in Q2 2018 and has held it in 33 quarters since.
- Swiss National Bank's Denali Therapeutics position peaked at $14.6M in Q4 2020.
- 124 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.